Daphnetin prevents methicillin-resistant Staphylococcus aureus infection by inducing autophagic response

Area of Science:

• Immunology
• Pharmacology
• Microbiology

Background:

• Bacterial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) presents a significant health threat due to increasing antibiotic resistance.
• Novel therapeutic strategies are urgently needed to combat drug-resistant bacterial infections.
• Daphnetin (DAPH), a natural coumarin derivative, possesses known anti-inflammatory, antimicrobial, and antioxidant properties.

Purpose of the Study:

• To investigate the protective effects of Daphnetin (DAPH) against Staphylococcus aureus-induced pneumonia.
• To elucidate the underlying mechanisms of DAPH's action, particularly its impact on the autophagic pathway.

Main Methods:

• Treatment of S. aureus-induced pneumonia models with Daphnetin (DAPH).
• Assessment of inflammatory responses, bacterial load, and lung tissue damage.
• Evaluation of the role of the mTOR-dependent autophagic pathway in DAPH's therapeutic effects.

Main Results:

• DAPH treatment significantly protected against S. aureus pneumonia, reducing inflammation, enhancing bacterial clearance, and alleviating tissue damage.
• DAPH markedly boosted the mTOR-dependent autophagic pathway in macrophages.
• Inhibition of the autophagic pathway abrogated DAPH's anti-inflammatory and antibacterial effects.

Conclusions:

• Daphnetin (DAPH) is a promising natural agent for combating bacterial pneumonia, including that caused by MRSA.
• DAPH enhances macrophage bactericidal activity and suppresses inflammation by activating the mTOR-dependent autophagic pathway.
• Targeting the autophagic pathway represents a potential therapeutic strategy for infectious diseases caused by antibiotic-resistant pathogens.